Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

See more

Impact factor 2024

4.4

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2024

9.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2024

1.011

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2024

1.057

View more metrics

Journal Information

Most often read

Vol. 31. Issue. 1

32194

Evolving portal hypertension through Baveno VII recommendations

Manuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos

Ann Hepatol. 2024;29:101180

32194

Full text access

Share

32011

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis

Shudi Li, Fei Duan, Suling Li, Baoping Lu

Ann Hepatol. 2024;29:101174

32011

Full text access

Share

29480

Alcohol-related liver disease: A global perspective

Graciela Elia Castro Narro, Luis Antonio Díaz, Eric Kauffman Ortega, María Fernanda Bautista Garín, Eira Cerda Reyes, Pindaro Sebastian Martinez Delfin, Juan Pablo Arab, Ramón Bataller

Ann Hepatol. 2024;29:101499

29480

Full text access

Share

15518

From NAFLD to MASLD: When metabolic comorbidity matters

Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei

Ann Hepatol. 2024;29:101281

15518

Full text access

Share

13938

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT

Jeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon

Ann Hepatol. 2024;29:101280

13938

Full text access

Share

11596

Why a pinch of zinc in liver disease matters

Kurt Grüngreiff, Dirk Reinhold, Wolfgang Maret

Ann Hepatol. 2024;29:101152

11596

Full text access

Share

11435

Pathophysiology of ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problem

Gabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, ... Héctor Solar

Ann Hepatol. 2024;29:101498

11435

Full text access

Share

10969

Alcohol-associated liver disease: Epidemiology and management

Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller

Ann Hepatol. 2024;29:101162

10969

Full text access

Share

10081

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease

Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam

Ann Hepatol. 2024;29:101512

10081

Full text access

Share

9653

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group

Ann Hepatol. 2024;29:101133

9653

Full text access

Share

9250

Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents

Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra

Ann Hepatol. 2024;29:101182

9250

Full text access

Share

8859

The burden of liver disease in Latin America

Luis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese

Ann Hepatol. 2024;29:101175

8859

Full text access

Share

7846

The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease

Mingkai Li, Ying Lin, Hongsheng Yu, Weichun Lin, Jianning Chen, Yidong Yang, Bin Wu

Ann Hepatol. 2024;29:101516

7846

Full text access

Share

7133

Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Bryan A. Priego-Parra, Arturo Triana-Romero, Génesis P. Martínez-Pérez, Sara A. Reyes-Diaz, Héctor R. Ordaz-Alvarez, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, ... José M. Remes-Troche

Ann Hepatol. 2024;29 Supl 2:101391

7133

Full text access

Share

6544

Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018

Tongtong Wang, Yuzhi Xi, Annaswamy Raji, Michael Crutchlow, Gail Fernandes, Samuel S Engel, Xiao Zhang

Ann Hepatol. 2024;29:101154

6544

Full text access

Share

5649

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease

Francisco Barrera, Javier Uribe, Nixa Olvares, Paula Huerta, Daniel Cabrera, Manuel Romero-Gómez

Ann Hepatol. 2024;29:101501

5649

Full text access

Share

5644

From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.

Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner

Ann Hepatol. 2024;29:101185

5644

Full text access

Share

5579

Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis

Adnan Malik, Muhammad Imran Malik, Shahbaz Qureshi, Abdul Nadir

Ann Hepatol. 2024;29:101495

5579

Full text access

Share

5357

Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells

Shuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He

Ann Hepatol. 2024;29:101279

5357

Full text access

Share

5319

Palliative care and end stage liver disease: A cohort analysis of palliative care use and factors associated with referral

Hugo M Oliveira, Helena Pessegueiro Miranda, Francisca Rego, Rui Nunes

Ann Hepatol. 2024;29:101518

5319

Full text access

Share

Article options

Tools